- Posted April 15, 2014 by
- Consumers Increasingly Becoming Concerned with Food Packaging Safety
- Seniors’ Narcotics Use Under Medicare is a Growing Concern – Report
- Growing Global Population Driving Force Behind Food Industry Mergers
- Pacific Shore Holdings, Inc. Aims to Become a Billion Company Within 5 Years in Green Scene Products Arena
- 52% More Restaurants to Offer Gluten-Free Dishes in 2014 – survey
Biocorrx Hits A High Note With Opioid Addiction Treatment
Publicly-listed BioCorRx (OTCQB: BICX) is an addiction treatment and rehabilitation company on the leading edge of substance in alcohol and substance abuse treatment. BioCorRx is known for its Start Fresh Program that combines life-coaching services back-to-back with the use of a proprietary implant developed by Dr. James Rowe of Australia.
“Our leaders founded BioCorRx, Inc. on the basis of wanting to help individuals break the cycle of addiction. Consisting of doctors, experts and even those who have experienced the vicious cycle of addiction firsthand, our leadership team is dedicated to the holistic approach of the Start Fresh Program”, according to the company website (http://www.startfreshprogram.com/leadership-team/).
Addressing Addiction In Whatever Form
Initially developed to address alcohol dependency, BioCorRx’s implant treatment allows the company to license physicians and medical groups experienced in treating drug and alcohol dependence, whether based in the U.S and abroad.
Using the medication Naltrexone, this implant serves to block the effects of alcohol, and was approved by the FDA in 1995 for the treatment of alcohol dependence. Research showed that naltrexone also works in negating the effects of the opioids narcotics, making it a potent weapon in the treatment of opioid addition. The FDA approved the use of naltrexone for the treatment of opioid abuse in 1984.
How Naltrexone Works
An opioid receptor antagonist used mainly in the treatment of alcohol and opioid dependence, naltrexone blocks the parts of the brain that “feel pleasure” when individuals use those substances. When these areas of the brain are blocked, individuals feel significantly less cravings for drugs and alcohol. And even if these substances are used, the effects will be extremely limited and the desire to continue drinking and using will be diminished. The removal of the physical cravings is critical so the individual can refocus on their life and the psychosocial aspect of their recovery. It is of particular importance during the notoriously difficult first six months of recovery.
Naltrexone is usually given in oral or injection form, making patients responsible for taking it or administered by a doctor. However, there is a drawback that it must be taken daily and a patient whose craving becomes overwhelming can obtain the euphoria simply by skipping a dose before resuming abuse. Patients who receive the program developed by BioCorRx are treated with a slow release dose via an implant that can last up to a year in many patients (depending on various factors such as metabolism rates), giving patients a higher success rate for the treatment of their addiction.
Thanks to BioCorRx’s technology, the implant procedure can take as little as 20 minutes under local anesthetic in some cases. Most patients can return to work or their daily routine the next day, without the cravings for alcohol or opioids.
Currently, the company is aligning its program to include opioid addiction treatment. According to the Centers for Disease Control, 100 Americans die each day from drug overdoses, about half of these overdose deaths involve at least one other drug, often alcohol. Prescription painkiller abuse is reaching epidemic proportions, with some states seeing as much as a 770% increase in treatment sought for opiate addiction over the last fifteen years. In 2010, more than 12 million people reported using painkillers nonmedically, which is a staggering statistic on its own prior to taking into consideration the cases that go unreported. All this abuse burdens the U.S healthcare system with an estimated annual cost of $72 billion.